Grufity logo
Grufity logo
BGNE

BGNE - BeiGene Ltd Stock Price, Fair Value and News

$257.47 
Delayed as of 04 Mar 2025, 04:00 pm ET

Price Targets

BGNE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BGNE Price Action

BGNE RSI Chart

BGNE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BGNE Valuation

Market Cap

392.6B

Price/Earnings (Trailing)

765.29

Price/Sales (Trailing)

68.41

EV/EBITDA

457.39

Price/Free Cashflow

352.24

BGNE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

BGNE Fundamentals

BGNE Revenue

Revenue (TTM)

5.7B

Rev. Growth (Yr)

35.46%

Rev. Growth (Qtr)

1.02%

BGNE Earnings

Earnings (TTM)

513.0M

Earnings Growth (Yr)

17.8K%

Earnings Growth (Qtr)

241.88%

BGNE Profitability

EBT Margin

11.42%

Return on Equity

10.78%

Return on Assets

6%

Free Cashflow Yield

0.28%

BGNE Investor Care

Shares Dilution (1Y)

3.97%

Diluted EPS (TTM)

0.34

BGNE Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
Revenue & Growth

How BeiGene Ltd generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20265.7B---
20254.2B4.6B5.0B5.3B
20242.8B3.1B3.3B3.8B
20231.6B1.8B2.2B2.5B
2022877.0M1.1B1.2B1.4B
2021862.7M947.0M1.1B1.2B
2020402.4M224.7M265.7M308.9M
2019243.5M434.1M430.0M428.2M
2018281.1M323.7M157.7M198.2M
2017--180.6M238.4M
20168.1M7.1M64.9M122.8M
201512.0M10.9M9.9M8.8M
2014---13.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About BeiGene Ltd

BGNE
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
 CEO
 WEBSITEbeigene.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES10000

BeiGene Ltd Frequently Asked Questions

BGNE is the stock ticker symbol of BeiGene Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Apr 30 2026, market cap of BeiGene Ltd is 392.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Apr 30 2026, BGNE's PE ratio (Price to Earnings) is 765.29 and Price to Sales (PS) ratio is 68.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BGNE PE ratio will change depending on the future growth rate expectations of investors.